Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome.

Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, UK.
Arthritis & Rheumatology (Impact Factor: 7.48). 02/2009; 60(2):619-25. DOI: 10.1002/art.24294
Source: PubMed

ABSTRACT Tumor necrosis factor receptor (TNFR)-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory condition caused by mutations in the TNFRSF1A gene. Unlike other autoinflammatory diseases in which anti-TNF therapy is largely a successful treatment option, therapy with the anti-TNF drug infliximab is often ineffective in patients with TRAPS. Moreover, in certain cases, infliximab actually triggers severe episodes of inflammation. The aim of this study was to elucidate the mechanisms underlying such a reaction.
Peripheral blood mononuclear cells (PBMCs) were obtained from patients with TRAPS. Both caspase 3 activity and NF-kappaB subunit activity were determined by enzyme-linked immunosorbent assay. Cytokine secretion was assessed using a specific customized human multiplex bead immunoassay kit.
Unlike findings in controls, cells from a family of 9 patients, all of whom carried the T50M mutation in TNFRSF1A, failed to respond to infliximab through proapoptotic induction of caspase 3 activity. Instead, we observed enhanced antiapoptotic c-Rel subunit activity, accompanied by a significant increase in secretion of the proinflammatory cytokines interleukin- 1beta (IL-1beta), IL-1 receptor, IL-6, IL-8, and IL-12.
Altered extracellular conformation of TNFRI, resulting from the T50M mutation in TNFRSF1A, results in failure of PBMCs to induce an apoptotic response to infliximab. We hypothesize that failure to shed infliximab-bound TNF/TNFRI from the cell surface of cells from patients with the T50M mutation triggers c-Rel activation, and that this leads to a marked increase in cytokine secretion and an increased proinflammatory response. In light of these findings, we strongly advise caution when prescribing infliximab as anti-TNF therapy to patients with TRAPS.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The periodic syndromes represent a heterogeneous group of disorders that can be very difficult for practicing physicians to diagnosis and treat. This article presents an orderly approach to hyperimmunoglobulin D syndrome; tumor necrosis factor receptor-1 periodic syndrome; familial Mediterranean fever; periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome; and cryopyrin-associated periodic syndromes by highlighting the disease presentation, diagnosis, pathogenesis, and treatment. Recent advances are also discussed.
    Current Allergy and Asthma Reports 11/2010; 10(6):398-404. · 2.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetische Fiebersyndrome oder hereditäre rekurrierende Fiebersyndrome (HRF) werden als Teil der autoinflammatorischen Erkrankungen (AID) angesehen, die auf Störungen im angeborenen (,,innate“) Immunsystem beruhen. Typisch für diese Erkrankungen sind selbstlimitierte Episoden mit Fieber und hohen Entzündungszeichen. Der Vererbungsmodus kann sowohl autosomal-rezessiv als auch autosomal-dominant sein. Die Vertreter dieser Erkrankungen sind das familiäre Mittelmeerfieber, Tumornekrosefaktorrezeptor-1-assoziiertes periodisches Syndrom, Hyper-IgD-Syndrom und Cryopyrin-assoziierte periodische Syndrome. Die als ,,deficiency of interleukin 1 receptor antagonist“ beschriebene Erkrankung gehört nur bedingt in diese Krankheitsgruppe, da das Fieber kein typisches Symptom ist. Die Therapie hängt von der Art und Schwere der Erkrankung ab. Für das familiäre Mittelmeerfieber besteht eine effektive Prophylaxe mit Colchizin. Für schwere Formen der HRF-Erkrankungen ist die Therapie mit Biologika, insbesondere die Blockade von Il-1, hocheffektiv. Mit dem Ziel, mehr Informationen über diese Erkrankungen zu dokumentieren, eine Biobank einzurichten und Forschungsprojekte zu initiieren, wurde das AID-Net-Projekt gegründet, das vom Bundesministerium für Bildung und Forschung finanziert wird. In das Register sind bisher 606 Patienten mit AID eingeschleust worden, davon haben 381 ein HRF.
    Zeitschrift für Rheumatologie 01/2013; 72(4). · 0.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autophagy prevents cellular damage by eliminating insoluble aggregates of mutant misfolded proteins, which accumulate under different pathological conditions. Downregulation of autophagy enhances the inflammatory response and thus represents a possible common pathogenic event underlying a number of autoinflammatory syndromes, such as tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS). The pathogenesis of other monogenic or complex disorders that display symptoms of excessive inflammation also involve the autophagy pathway. Studies have shown that TRAPS-associated TNFRSF1A mutations induce cytoplasmic retention of the TNFR1 receptor, defective TNF-induced apoptosis, and production of reactive oxygen species (ROS). Furthermore, autophagy impairment may account for the pathogenic effects of TNFRSF1A mutations, thus inducing inflammation in TRAPS. In this review, we summarize the molecular interactions and functional links between autophagy with regard to nuclear factor-kappa B activation, ROS production, and apoptosis. Furthermore, we propose a complex interplay of these pathways as a model to explain the relationship between mutant protein misfolding and inflammation in genetically determined and aggregation-prone diseases. Accordingly, autophagy function should be investigated in all diseases showing an inflammatory component, and for which the molecular pathogenesis is still unclear.
    Journal of Molecular Medicine 04/2014; · 4.77 Impact Factor


Available from
Jun 2, 2014